查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1504255

全球真实世界证据（RWE）解决方案市场评估：依组件、依应用、按收入模式、依部署方法、依最终用户、依地区、机会、预测（2017-2031）

Real-World Evidence Solutions Market Assessment, By Component, By Application, By Revenue Model, By Mode of Deployment, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 215 Pages | 商品交期: 3-5个工作天内

价格

全球真实世界证据（RWE）解决方案市场规模预计将从2023年的 18.6 亿美元增至2031年的 44.8 亿美元，年复合成长率预计将成长 11.57%。该市场近年来呈现显着成长，预计未来将保持强劲的扩张速度。

现实世界证据（RWE）解决方案市场是医疗和生命科学领域一个充满活力且快速扩张的市场。 RWE 指的是来自真实病患体验和医疗程序的资讯和见解，而不是来自对照临床研究的资料。近年来，由于其改善患者治疗效果、加速药物开发和指导医疗决策的潜力，该市场变得越来越突出。由于多个关键方面的原因，市场不断成长。首先，对现实世界证据解决方案的需求是由对循证医学的日益重视以及卫生系统利益相关者做出明智决策的需求所推动的。 RWE 可用于评估医疗干预措施（例如药物和设备）针对不同患者群体的安全性和有效性。这有助于了解现实世界中的患者结果、疾病发生和治疗结果。此外，电子健康记录（EHR）和数位健康技术的激增提供了可用于 RWE 分析的大量资料。 RWE 解决方案市场的成长得益于医疗保健行业中大资料分析、机器学习和人工智慧的集成，实现了对现实世界资料的有效收集、管理和分析。 RWE 解决方案的主要最终用户是製药公司，它们促进市场进入、上市后监督和药物开发。 RWE 被付款人、医疗保健提供者和监管机构用来就药物批准、支付政策和治疗指南做出明智的决定。如此广泛的应用显示了市场适应性和扩展空间。例如，在第31届Conference on Retroviruses and Opportunistic Infections（CROI2024）上，Gilead Sciences, Inc.宣布将于2024年2月展示其抗病毒研发计画的RWE和新的临床资料。关于 HIV、COVID-19 和病毒性肝炎的四项口头报告和最新资讯预计也将包含在约 80 项研究的资料中。

对实证医学的日益关注推动市场成长

全球真实世界证据（RWE）解决方案市场的扩张可归因于对实证医学的重视。当资料驱动的决策在医疗保健产业变得越来越重要时，RWE 已成为影响医疗实践、药物开发和健康政策的强大技术。真实世界证据（RWE）对于实证医学过程非常重要，实证医学基于最佳可用临床资料的选择。真实世界证据（RWE）越来越受到付款人、製药公司、监管机构和医生等医疗保健利益相关者的重视，以提高医疗保健服务的有效性和品质。儘管临床试验很重要，但在准确代表现实世界的患者群体方面常常存在问题。然而，RWE 捕捉了更广泛的患者人口统计和临床场景，并提供了有关医疗干预和治疗在不同现实环境中如何发挥作用的见解。

关注实证医学并应用RWE对于研发，尤其是製药业非常有利。 RWE 帮助製药公司在现实临床环境中收集患者资料，以揭示药物和治疗的有效性和安全性。这些资讯有助于为药物开发的多个阶段的决策提供信息，从选择目标患者人群到规划更有效的临床试验和上市后监测。而且它不仅限于临床试验的受控环境。付款人和监管机构依靠 RWE 的见解就药品审批、市场准入和偿付政策做出明智的决策。他们透过评估医疗干预措施的临床影响和现实成本效益，确保公平地获得最佳治疗并优化资源分配。

本报告研究和分析了全球真实世界证据（RWE）解决方案市场，提供市场规模和预测、市场动态以及主要参与者的现状和前景。

目录

第1章 研究方法

第2章 专案范围与定义

第3章 执行摘要

第4章 全球真实世界证据（RWE）解决方案市场展望（2017-2031年）

  • 市场规模与预测
    • 金额
  • 依组件
    • 服务
    • 资料集
  • 依用途
    • 药物开发与审批
    • 医疗器材的开发与审批
    • 上市后监测
    • 市场进入和赎回
    • 临床与监管决策
  • 依获利模式
    • 基于价值的定价
    • 基于订阅
  • 依部署方法
    • 本地
    • 基于云端
  • 依最终用户
    • 製药公司
    • 医疗器材公司
    • 医疗保险公司
    • 医疗保健提供者
    • 其他
  • 依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东、非洲
  • 市占率：依公司划分（2023年）

第5章 全球真实世界证据（RWE）解决方案市场展望：依地区划分（2017-2031年）

  • 北美
    • 市场规模与预测
    • 依组件
    • 依用途
    • 依获利模式
    • 依部署方法
    • 依最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳洲
    • 越南
    • 韩国
    • 印尼
    • 菲律宾
  • 南美洲
    • 巴西
    • 阿根廷
  • 中东、非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第6章 市场地图（2023年）

  • 依组件
  • 依用途
  • 依获利模式
  • 依部署方法
  • 依最终用户
  • 依地区

第7章 宏观环境与产业结构

  • 需求与供给分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第8章 市场动态

  • 生长促进因素
  • 抑製成长的因素（问题、限制因素）

第9章 监理架构与创新

  • 专利情况
  • 监理机关的核准
  • 创新/新技术

第10章 主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析（2023年）
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家市场公司）
  • 专利分析（如果适用）

第11章 案例研究

第12章 主要公司展望

  • IQVIA Inc.
  • Kaia Health Software, Inc.
  • Thermo Fisher Scientific Inc.
  • Merative L.P.
  • Optum, Inc.
  • ICON plc
  • Parexel International (MA) Corporation
  • Syneos Health
  • PerkinElmer, Inc.
  • Datavant, Inc.

第13章 战略建议

第14章 关于本公司，免责声明

Product Code: MX11531

Global real-world evidence solutions market is projected to witness a CAGR of 11.57% during the forecast period 2024-2031F, growing from USD 1.86 billion in 2023 to USD 4.48 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

The real-world evidence (RWE) solutions market is a vibrant and fast-expanding market within the healthcare and life sciences sector. Rather than data from controlled clinical studies, RWE refers to information and insights from actual patient experiences and healthcare procedures. Due to its potential to improve patient outcomes, increase medication development, and guide healthcare decisions, this market has become increasingly prominent in recent years. The global RWE solutions market is growing as a result of several important aspects. First and foremost, the need for real-world evidence solutions is driven by the growing emphasis on evidence-based medicine and the healthcare system's stakeholders' requirement to make informed decisions. RWE is useful for assessing the safety and efficacy of medical interventions, such as drugs and devices, on a variety of patient groups. This facilitates comprehension of patient outcomes in real-world contexts, illness development, and therapy outcomes. Moreover, a multitude of data that may be utilised for RWE analysis has been made possible by the widespread use of electronic health records (EHRS) and digital health technology. The market for RWE solutions has grown as a result of the effective gathering, management, and analysis of real-world data made possible by the integration of big data analytics, machine learning, and artificial intelligence in the healthcare industry. Among the main end-users of RWE solutions are pharmaceutical businesses, which utilize them to assist market entry, post-market surveillance, and drug development. RWE is utilized by payers, healthcare providers, and regulatory authorities to make well-informed decisions about drug approvals, payment policies, and treatment guidelines. This wide range of applications demonstrates the market's adaptability and room for expansion. For instance, at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), Gilead Sciences, Inc. announced in February 2024 that it would present RWE and new clinical data from its antiviral research and development programs. Four oral presentations and the latest information on HIV, COVID-19, and viral hepatitis were also expected to be included in the data, which comes from nearly 80 studies.

Growing Emphasis on Evidence-Based Medicine Leads to Market Growth

The expansion of the global real-world evidence (RWE) solutions market can be attributed to the emphasis on evidence-based medicine. RWE has become a potent technology that influences medical practices, pharmaceutical development, and healthcare policy in an era where data-driven decision-making is becoming increasingly important in the healthcare industry. Real-world evidence is crucial to the process of evidence-based medicine, which is based on choices of the best available clinical data. Real-world evidence is becoming more and more valued by healthcare stakeholders, such as payers, pharmaceutical firms, regulators, and physicians, to improve the effectiveness and quality of healthcare services. Despite its importance, clinical trials frequently have problems while correctly representing the patient population in the actual world. However, RWE captures a wider range of patient demographics and clinical scenarios and offers insights into how healthcare interventions and therapies function in various real-world settings.

The focus on evidence-based medicine and the application of RWE has been extremely beneficial for research and development, particularly for the pharmaceutical industry. It helps pharmaceutical corporations collect data from patients in actual healthcare settings, highlighting their medications' and treatments' efficacy and safety. This information helps with decision-making at several stages of drug development, from selecting target patient populations to planning more effective clinical trials and post-market surveillance. It also goes beyond the controlled setting of clinical trials. Payers and regulatory bodies utilize the insights by RWE to make well-informed decisions concerning medicinal approvals, market access, and reimbursement policies. They guarantee fair access to the best therapies and optimize resource allocation by assessing the clinical impact and real-world cost-effectiveness of healthcare interventions.

For example, in February 2024, Datavant, Inc. and PINC AI Applied Sciences (PAS), which is a division of Premier, Inc., extended their cooperation to advance trial diversity and equity, improve clinical trial operations, and advance healthcare research. The goal of this partnership is to accelerate the creation of novel treatments and solutions that will improve patient outcomes. To link clinical trial data with PAS's real-world data (RWD) and produce RWE that spurs innovation in clinical research, PAS will make use of Datavant, Inc.'s trial tokenization technology and data connectivity platform. This program provides deeper understanding of the efficacy and safety of medical interventions in real-world settings beyond the controlled environments of clinical trials.

Patient-Centric Healthcare Leading to Market Expansion

In addition to revolutionizing healthcare delivery, the idea of patient-centric healthcare is also driving growth in the global market for real-world evidence (RWE) solutions. Patient-centric healthcare prioritizes the experiences, preferences, and results of the patient at the center of the decision-making process. This philosophical change in healthcare directly and significantly impacts the acceptance and growth of RWE solutions. Patient-centric healthcare places a strong emphasis on the value of understanding the patient's viewpoint and life experiences. Data on treatment choices, quality of life after the treatment, outcomes reported by patients, and therapy adherence are all part of this process. This patient-generated data, which offers a thorough picture of the patient's journey and their reactions to medical procedures, is essential for RWE analysis. Furthermore, a constant flow of patient-generated data is produced by patients actively participating in self-care, which is made possible by digital health technologies and patient engagement tools. Patients can track their health and communicate in real time about their experiences with wearable technology, smartphone apps, and telemedicine platforms. To further enhance the real-world data utilized in healthcare decision-making, RWE solutions have the possibility to access a multitude of information directly from patients in this data-rich environment.

The need for RWE solutions that can integrate a wider range of real-world data sources, such as electronic health records, claims data, and social determinants of health, is driven by patient-centric healthcare in addition to patient-generated data. Healthcare stakeholders are encouraged to consider a wide range of elements that impact patients' well-being, from socioeconomic conditions to lifestyle choices, by emphasizing holistic patient care. Additionally, collaborative decision-making-in which patients actively engage in conversations regarding the advantages, disadvantages, and possible courses of treatment-is encouraged by patient-centric healthcare. By giving patients and medical professionals evidence-based insights into the efficacy and safety of different treatment options in the real world, RWE solutions facilitate shared decision-making. For example, the TSX Implant was first presented in Japan in February 2024 by ZimVie, Inc., a global player in the life sciences sector with a focus on the dentistry and spine sectors. With the goal of delivering advantages such as peri-implant health, sustained osseointegration, crestal bone preservation, and prosthetic stability, this implant incorporates design elements supported by more than two decades of clinical and RWD experience, hence improving patient experience and giving them better quality results.

Increasing Dominance of Drug Development Segment Fuels Market Growth

The global real-world evidence (RWE) solutions market has grown significantly, and one of the main drivers of this growth has been pharmaceutical research and development (R&D). The way the pharmaceutical business conducts research has been changing, and it now relies more and more on real-world evidence to guide and expedite the medication development process. This change has been a major factor behind the increasing demand for RWE solutions since they provide pharmaceutical organizations with useful information and efficiency-boosting chances at different phases of the drug development process. RWE contributes significantly to pharmaceutical R&D by offering important insights regarding the efficacy and safety of medications and treatments in real-world settings. Traditional clinical trials are carried out in carefully regulated settings with stringent inclusion and exclusion criteria, which may not accurately reflect the wide range of patient groups and clinical circumstances seen in everyday practice. RWE fills this void by providing an abundance of information gathered from actual patients in typical healthcare environments. Pharmaceutical companies can utilize this data to target patients more precisely, conduct clinical trials that are more successful and economical, and even look into new therapeutic indications according to their current medications.

Moreover, RWE is essential for post-market surveillance, which helps to keep an eye on the efficacy and safety of medications and medical devices after they are made available to the general public. RWE is used by pharmaceutical businesses and regulatory bodies, including the U.S. Food and Drug Administration (FDA), to identify adverse events, evaluate the long-term efficacy of medications, and make well-informed judgments about safety alerts. The prompt and thorough monitoring contributes to the preservation of pharmaceutical products' reliability and safety in the marketplace. Additionally, RWE makes comparative effectiveness research easier, giving pharmaceutical companies insight into how their products perform in real-world patient populations relative to competitors. They can use this knowledge to better distinguish between their products, find areas of development, and overcome obstacles for easier market entry. For example, Thermo Fisher Scientific Inc. acquired CorEvitas LLC in July 2023 for a total of USD 912.5 million with the intention of bolstering its real-world, regulatory-grade evidence for licensed medical treatments and therapies to enhance its drug development segment.

North America to Dominate the Real-World Evidence Solutions Market

With the biggest market share in the world, the real-world evidence solutions market, North America emerged as the leading participant. The use of real-world evidence in healthcare decision-making has been supported by regulations more and more throughout North America, especially in the United States. Real-world data is valuable, and regulatory bodies like the United States Food and Drug Administration (FDA) have begun incorporating it into their decision-making procedures, such as post-market surveillance and drug approvals. There is a sizable pharmaceutical and life sciences sector in North America. These sectors have a significant stake in the global real-world evidence solutions market because they depend on real-world data to guide drug research, prove drug efficacy, and facilitate access to markets. For example, in the Federal Food, Drug, & Cosmetic Act (FD&C Act) of North America, Section 505-F (b) defines RWE as "data concerning the use, or potential benefits or challenges, of a drug obtained from sources apart from traditional clinical trials." The presence of numerous pharmaceutical companies in North America drives the demand for real-world evidence solutions.

For example, the FDA announced the launch of the Advancing Real World Evidence Program in October 2022. Enhancing the quality and acceptability of RWE-based approaches to support new labeling claims, such as accepting new applications for already-approved medical products or fulfilling post-approval research requirements, is the goal of this program. This program is a component of the FDA's commitment as stated in the FDA User Fee Reauthorization Act of 2022, which includes the Prescription Drug User Fee Act VII.

Future Market Scenario (2024-2031F)

The main factors contributing to the anticipated growth of the real-world evidence solutions market are the increasing prevalence of chronic disorders, increasing emphasis on evidence-based medicine and increasing demand for patient-centric healthcare services. Rising awareness in people and the need are also factors that will always propel the market growth in the future. Given that technology is advancing, cutting-edge technology in the area can also be expected. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, the FDA released draft guidance in December 2023 on how it evaluates real-world data (RWD) when determining whether to approve or clear a medical device by providing anonymized examples of its RWE utilization.

Key Players Landscape and Outlook

Several companies such as IQVIA Inc., Kaia Health Software, Inc., Thermo Fisher Scientific Inc., Merative L.P., Optum, Inc., ICON plc, Parexel International (MA) Corporation, Syneos Health, PerkinElmer, Inc., Datavant, Inc., etc., are expanding business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launches of newly developed RWE solutions to help researchers and to bring up their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments and partnerships are a few ways through which they are trying to achieve the same.

Palantir Technologies Inc. and Parexel International (MA) Corporation collaborated in April 2024 to use AI to speed up and improve the delivery of efficient and secure clinical trials for clients in the global biopharmaceutical industry. Through this collaboration, Paraxel International (MA) Corporation is able to further develop its skills in advanced analytics, RWE, and health outcomes, as well as improve its clinical trial processes.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Real-World Evidence Solutions Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. By Component
    • 4.2.1. Services
    • 4.2.2. Data Sets
      • 4.2.2.1. Disparate Data Sets
        • 4.2.2.1.1. Clinical Settings Data Sets
        • 4.2.2.1.2. Claims Data Sets
        • 4.2.2.1.3. Pharmacy Data Sets
        • 4.2.2.1.4. Patient-Powered Data Sets
        • 4.2.2.1.5. Registry-Based Data Sets
      • 4.2.2.2. Integrated Data Sets
  • 4.3. By Application
    • 4.3.1. Drug Development and Approvals
      • 4.3.1.1. Oncology
      • 4.3.1.2. Cardiology
      • 4.3.1.3. Neurology
      • 4.3.1.4. Immunology
      • 4.3.1.5. Other Therapeutic Areas
    • 4.3.2. Medical Device Development and Approvals
    • 4.3.3. Post-Market Surveillance
    • 4.3.4. Market Access and Reimbursement
    • 4.3.5. Clinical and Regulatory Decision Making
  • 4.4. By Revenue Model
    • 4.4.1. Value-Based Pricing
    • 4.4.2. Subscription-Based
  • 4.5. By Mode of Deployment
    • 4.5.1. On-Premises
    • 4.5.2. Cloud-Based
  • 4.6. By End-user
    • 4.6.1. Pharmaceutical Companies
    • 4.6.2. Medical Device Companies
    • 4.6.3. Healthcare Payers
    • 4.6.4. Healthcare Providers
    • 4.6.5. Others
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. Asia-Pacific
    • 4.7.4. South America
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Real-World Evidence Solutions Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
    • 5.1.2. By Component
      • 5.1.2.1. Services
      • 5.1.2.2. Data Sets
        • 5.1.2.2.1. Disparate Data Sets
          • 5.1.2.2.1.1. Clinical Settings Data Sets
          • 5.1.2.2.1.2. Claims Data Sets
          • 5.1.2.2.1.3. Pharmacy Data Sets
          • 5.1.2.2.1.4. Patient-Powered Data Sets
          • 5.1.2.2.1.5. Registry-Based Data Sets
        • 5.1.2.2.2. Integrated Data Sets
    • 5.1.3. By Application
      • 5.1.3.1. Drug Development and Approvals
        • 5.1.3.1.1. Oncology
        • 5.1.3.1.2. Cardiology
        • 5.1.3.1.3. Neurology
        • 5.1.3.1.4. Immunology
        • 5.1.3.1.5. Other Therapeutic Areas
      • 5.1.3.2. Medical Device Development and Approvals
      • 5.1.3.3. Post-Market Surveillance
      • 5.1.3.4. Market Access and Reimbursement
      • 5.1.3.5. Clinical and Regulatory Decision Making
    • 5.1.4. By Revenue Model
      • 5.1.4.1. Value-Based Pricing
      • 5.1.4.2. Subscription-Based
    • 5.1.5. By Mode of Deployment
      • 5.1.5.1. On-Premises
      • 5.1.5.2. Cloud-Based
    • 5.1.6. By End-user
      • 5.1.6.1. Pharmaceutical Companies
      • 5.1.6.2. Medical Device Companies
      • 5.1.6.3. Healthcare Payers
      • 5.1.6.4. Healthcare Providers
      • 5.1.6.5. Others
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
        • 5.1.7.1.1. By Value
      • 5.1.7.2. By Component
        • 5.1.7.2.1. Services
        • 5.1.7.2.2. Data Sets
          • 5.1.7.2.2.1. Disparate Data Sets
          • 5.1.7.2.2.1.1. Clinical Settings Data Sets
          • 5.1.7.2.2.1.2. Claims Data Sets
          • 5.1.7.2.2.1.3. Pharmacy Data Sets
          • 5.1.7.2.2.1.4. Patient-Powered Data Sets
          • 5.1.7.2.2.1.5. Registry-Based Data Sets
          • 5.1.7.2.2.2. Integrated Data Sets
      • 5.1.7.3. By Application
        • 5.1.7.3.1. Drug Development and Approvals
          • 5.1.7.3.1.1. Oncology
          • 5.1.7.3.1.2. Cardiology
          • 5.1.7.3.1.3. Neurology
          • 5.1.7.3.1.4. Immunology
          • 5.1.7.3.1.5. Other Therapeutic Areas
        • 5.1.7.3.2. Medical Device Development and Approvals
        • 5.1.7.3.3. Post-Market Surveillance
        • 5.1.7.3.4. Market Access and Reimbursement
        • 5.1.7.3.5. Clinical and Regulatory Decision Making
      • 5.1.7.4. By Revenue Model
        • 5.1.7.4.1. Value-Based Pricing
        • 5.1.7.4.2. Subscription-Based
      • 5.1.7.5. By Mode of Deployment
        • 5.1.7.5.1. On-Premises
        • 5.1.7.5.2. Cloud-Based
      • 5.1.7.6. By End-user
        • 5.1.7.6.1. Pharmaceutical Companies
        • 5.1.7.6.2. Medical Device Companies
        • 5.1.7.6.3. Healthcare Payers
        • 5.1.7.6.4. Healthcare Providers
        • 5.1.7.6.5. Others
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Component
  • 6.2. By Application
  • 6.3. By Revenue Model
  • 6.4. By Mode of Deployment
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Value Chain Analysis
  • 7.3. PESTEL Analysis
    • 7.3.1. Political Factors
    • 7.3.2. Economic System
    • 7.3.3. Social Implications
    • 7.3.4. Technological Advancements
    • 7.3.5. Environmental Impacts
    • 7.3.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.4. Porter's Five Forces Analysis
    • 7.4.1. Supplier Power
    • 7.4.2. Buyer Power
    • 7.4.3. Substitution Threat
    • 7.4.4. Threat From New Entrant
    • 7.4.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Case Studies

12. Key Players Outlook

  • 12.1. IQVIA Inc.
    • 12.1.1. Company Details
    • 12.1.2. Key Management Personnel
    • 12.1.3. Products and Services
    • 12.1.4. Financials (As Reported)
    • 12.1.5. Key Market Focus and Geographical Presence
    • 12.1.6. Recent Developments
  • 12.2. Kaia Health Software, Inc.
  • 12.3. Thermo Fisher Scientific Inc.
  • 12.4. Merative L.P.
  • 12.5. Optum, Inc.
  • 12.6. ICON plc
  • 12.7. Parexel International (MA) Corporation
  • 12.8. Syneos Health
  • 12.9. PerkinElmer, Inc.
  • 12.10. Datavant, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 3. Global Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 4. Global Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 5. Global Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 6. Global Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Real-World Evidence Solutions Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 10. North America Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 11. North America Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 12. North America Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 13. North America Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Real-World Evidence Solutions Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 17. United States Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 18. United States Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 19. United States Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 20. United States Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 23. Canada Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 24. Canada Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 25. Canada Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 26. Canada Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 29. Mexico Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 30. Mexico Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 31. Mexico Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 32. Mexico Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 35. Europe Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 36. Europe Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 37. Europe Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 38. Europe Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Real-World Evidence Solutions Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 42. Germany Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 43. Germany Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 44. Germany Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 45. Germany Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 48. France Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 49. France Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 50. France Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 51. France Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 54. Italy Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 55. Italy Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 56. Italy Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 57. Italy Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 60. United Kingdom Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 61. United Kingdom Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 62. United Kingdom Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 63. United Kingdom Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 66. Russia Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 67. Russia Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 68. Russia Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 69. Russia Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 72. Netherlands Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 73. Netherlands Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 74. Netherlands Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 75. Netherlands Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 78. Spain Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 79. Spain Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 80. Spain Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 81. Spain Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 84. Turkey Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 85. Turkey Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 86. Turkey Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 87. Turkey Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 90. Poland Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 91. Poland Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 92. Poland Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 93. Poland Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 96. South America Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 97. South America Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 98. South America Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 99. South America Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Real-World Evidence Solutions Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 103. Brazil Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 104. Brazil Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 105. Brazil Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 106. Brazil Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 109. Argentina Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 110. Argentina Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 111. Argentina Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 112. Argentina Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 115. Asia-Pacific Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 116. Asia-Pacific Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 117. Asia-Pacific Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 118. Asia-Pacific Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Real-World Evidence Solutions Market Share (%), By Country, 2017-2031F
  • Figure 120. India Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 122. India Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 123. India Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 124. India Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 125. India Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 128. China Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 129. China Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 130. China Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 131. China Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 134. Japan Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 135. Japan Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 136. Japan Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 137. Japan Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 140. Australia Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 141. Australia Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 142. Australia Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 143. Australia Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 146. Vietnam Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 147. Vietnam Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 148. Vietnam Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 149. Vietnam Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 152. South Korea Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 153. South Korea Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 154. South Korea Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 155. South Korea Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 158. Indonesia Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 159. Indonesia Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 160. Indonesia Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 161. Indonesia Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 164. Philippines Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 165. Philippines Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 166. Philippines Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 167. Philippines Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 170. Middle East & Africa Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 171. Middle East & Africa Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 172. Middle East & Africa Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 173. Middle East & Africa Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Real-World Evidence Solutions Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 177. Saudi Arabia Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 178. Saudi Arabia Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 179. Saudi Arabia Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 180. Saudi Arabia Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 183. UAE Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 184. UAE Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 185. UAE Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 186. UAE Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Real-World Evidence Solutions Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Real-World Evidence Solutions Market Share (%), By Component, 2017-2031F
  • Figure 189. South Africa Real-World Evidence Solutions Market Share (%), By Application, 2017-2031F
  • Figure 190. South Africa Real-World Evidence Solutions Market Share (%), By Revenue Model, 2017-2031F
  • Figure 191. South Africa Real-World Evidence Solutions Market Share (%), By Mode of Deployment, 2017-2031F
  • Figure 192. South Africa Real-World Evidence Solutions Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Component Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Revenue Model Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Mode of Deployment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023